

# EFFICACY AND MARGINAL COST OF TREATMENT WITH TOCILIZUMAB IN COVID-19 PATIENTS Garcia Molina, A; Alos



5PSQ-058

Almiñana, M; Sánchez Martínez, R, Antón Hernández, M; Ferriols Lisart, R.

#### **OBJECTIVES**

The aim of this study is to evaluate overall survival of patients treated with Tocilizumab and the factors that influence survival. In addition, the marginal cost of treatment with Tocilizumab is analyzed.

## MATERIALS AND METHODS



Patients older than 18 years

SARS-COV2 positive

At least one dose of tocilizumab

### Cohorts

ICU (n = 87)

(n = 421)

Non-ICU

\*Admission site at the time of the first dose of tocilizumab

## Cost analysis

MC/RMST MC/YLG MC/SV


RMST: Restringed medium survival


time

MC: Marginal cost YLG: Years life gained

SV: survivor

#### RESULTS





Subgrupo	n	RMST (years)	MC/RMST (€/year)	MC/YLG(€)	CM/SV(€)
Global	508	0,761	534.07	530 €	552 €
Severity					
UCI	87	0,676	654,51	666€	675€
Non-UCI	421	0,764	532,81	579 €	551 €
Age					
Older than 71,5	199	0,581	697.84	701 €	726 €
Younger than 71,5	309	0,872	466,82	467 €	477 €

#### CONCLUSIONS

Treatment with Tocilizumab in patients with COVID-19 is more effective in patients admitted to the non-ICU vs. ICU. In addition, survival is higher in younger patients aged 71.5 years. The mean cost of treatment with Tocilizumab was €534.07/year